Development and validation method for the determination of related substances in nimesulide granules for oral suspension
Keywords:analytical chemistry method, nimesulide, method HPLC, granules for oral suspension, limits for impurities, validation
One of the key stages of pharmaceutical development is the development of analytical methods for quality control of medicines. The critical quality indicator is the content of related impurities, which may increase during shelf life of the product due to the degradation of the active substance, which in turn affects the quality of the product.
The aim of the work is to develop and validate the method for the determination of related impurities in nimesulide granules for oral suspension by HPLC method; to set the specification of finished product for related impurities.
Materials and methods. Sample of finish product Nimesulide, granules for oral suspension, 100 mg/2 g, it was manufactured by JSC “Farmak”. The study was performed using Agilent 1260 liquid chromatograph with UV detector. 2-phenoxyaniline from Sigma-Aldrich, reference standards of nimesulide impurity D EP CRS and LGC, Nimesulide for peak identification EP CRS were used for preparation of standard impurity solutions. Acetonitrile and ammonium dihydrogen phosphate from Sigma-Aldrich were used for chromatographic analysis.
Results. When developing method, the concentrations of solutions, the method of dissolving granules, filters were selected. The chromatographic column was selected, the requirements for the chromatographic system suitability were set. The effect of placebo components has been studied and considered. During the validation the characteristics were studied: specificity, linearity, LOD, LOQ, precision, accuracy, robustness. The limits of the impurity content were established in accordance with the requirements of ICH Q3B guideline, taking into account the data of stress studies, stability and impurities of the substance.
Conclusions. The analytical method for the determination of related substances in finish product nimesulide granules for oral suspension was developed. The validation results showed that the method is suitable for analysis. The specification limits of finished product for related impurities were set.
European Medicines Agency. (2017). ICH Guideline Q8 (R2) on Pharmaceutical Development. Step 5 (EMEA/СHМР/167068/2004). https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-11.pdf
Berest, H. H., Lukina, I. A., Bihdan, O. A. (2017) Farmatsevtychnyi analiz likarskykh zasobiv [Pharmaceutical analysis of drugs] (Vol. 2). Zaporizhzhia: ZDMU. [in Ukrainian].
Gureyeva, S. M., Kondratova, Yu. A. (2016) Vyvchennia stabilnosti likarskoho zasobu Antral, tabletky, vkryti obolonkoiu [Stability studying of antral film-coated tablets]. Farmatsevtychnyi zhurnal, (2), 70-76. [in Ukrainian].
World Health Organization (2009). Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, Annex 2. In WHO Technical Report Series, No. 953.
European Medicines Agency (2020). ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Step 5 (CPMP/ICH/367/96). https://www.ema.europa.eu/documents/scientific-guideline/ich-q-6-test-procedures-acceptance-criteria-new-drug-substances-new-drug-products-chemical_en.pdf
Pikhlak, A. E., Garg, A., Gupta, N., Khandarkar, S., & Akku, S. (2018). Efficacy and Safety of Nimesulide in the Complex Treatment of Patients with Knee and Hip Osteoarthritis. EC Orthopaedics, 9(1), 12-18.
Zazirnyi, I. M. (2018). Efektyvnist zastosuvannia preparatu Nimedar ne postupaietsia efektyvnosti zastosuvannia preparatu Nimesyl v ortopedychnii praktytsi (prospektyvne doslidzhennia) [The effectiveness of Nimedar is not inferior to the effectiveness of Nimesil in orthopedic practice (prospective study)]. Travma, 19(6), 19-27. [in Ukrainian]. https://doi.org/10.22141/1608-1706.6.19.2018.152217
European Pharmacopoeia Commission, & European Directorate for the Quality of Medicines & Healthcare. Monograph No. 453 Nimesulide (01/2017:1548). In European Pharmacopoeia, 10th ed., Supplement 10.7; Council of Europe: Strasbourg, 2010.
State Enterprise Ukrainian Scientific Pharmacopoeial Center of Medicines Quality. (2015). Derzhavna Farmakopeya Ukrayiny [The State Pharmacopoeia of Ukraine] (Vol. 1, 2nd ed.). Kharkiv: State Enterprise Ukrainian Scientific Pharmacopoeial Center of Medicines Quality. [in Ukrainian].
FDA. (1996). Guideline for Industry. ICH Q2B Validation of Analytical Procedure: Methodology. https://www.gmp-compliance.org/files/guidemgr/1-12-5.pdf
European Medicines Agency. (2006). ICH Topic Q3B (R2) Impurities in New Drug Products. Step 5 Note for Guidance on Impurities in New Drug Products (CPMP/ICH/2738/99). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-3-b-r2-impurities-new-drug-products-step-5_en.pdf
Kovaříková, P., Mokrý, M., & Klimeš, J. (2003). Photochemical stability of nimesulide. Journal of Pharmaceutical and Biomedical Analysis, 31(4), 827-832. https://doi.org/10.1016/S0731-7085(02)00659-3
Kiran, G. U., Gurupadayya, B. M., Keshava, S. G., Jakkam, R., Dahake, M. N., & Eedara, S. R. (2020). Analytical method development and validation for the impurities of formulated nimesulide granules by RP-HPLC method. Journal of Global Trends in Pharmaceutical Sciences, 11(3), 8294-8299.
Nagulakonda, N. N. M., Ananthula, R. S., Susarla, K. P. C., Krishnamurthy, T., & Gollapalli, N. R. (2017). Quantification and in silico toxicity assessment of nimesulide and its related substances. Journal of Chromatographic Science, 55(5), 508-517. https://doi.org/10.1093/chromsci/bmx003
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)